This week's happenings: Vaccitech, Adapttech, Evidation
Vaccitech Raises $168M in Series B Financing
Vaccitech Ltd, an Oxford, UK – based clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, raised $168m in Series B financing.
The round was led by M&G Investment Management (part of M&G plc), with further participation from new investors Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Future Planet Capital among others.
Led by Bill Enright, Chief Executive Officer, Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer.
The proceeds from the financing will support the development of three infectious disease and immuno-oncology programs. The programs include:
- A Phase 1/2 clinical trial of VTP-300 in patients with chronic hepatitis B virus (HBV) infection. The first patient in the trial was dosed in February 2021.
- A Phase 1/2 clinical trial of VTP-200 in patients with persistent, high-risk human papillomavirus (HPV) infection.
- A Phase 1/2 clinical trial of VTP-850 in combination with a checkpoint inhibitor in patients with prostate cancer.
-
Vaccitech Raises $168M in Series B Financing | FinSMEs
Vaccitech Ltd, an Oxford, UK – based clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, raised $168m in Series B financing
Amphista Therapeutics Raises $53M in Series B Funding
Amphista Therapeutics, a Glasgow, Scotland, UK-based leader in next generation targeted protein degradation (TPD) approaches, closed a $53m (£38m) Series B financing round.
The round was co-led by Forbion and Gilde Healthcare with participation from Novartis Venture Fund, and Eli Lilly and Company, and existing investor BioMotiv and founding investor Advent Life Sciences.
The company intends to use the funds to accelerate its pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and to extend its proprietary TPD platform.
Led by CEO Nicola Thompson, Amphista Therapeutics is a biopharmaceutical company creating therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease-causing proteins. The company’s pipeline of novel targeted protein degradation (TPD) based medicines is focused on challenging diseases including cancer.
https://www.finsmes.com/2021/03/amphista-therapeutics-raises-53m-in-series-b-funding.html
PhoreMost Raises $46M in Series B Financing
PhoreMost Ltd., a Cambridge, England, UK-based biopharmaceutical company, raised $46m in Series B funding.
The round was led by BGF, and included new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures. Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.
The company intends to use the funds to progress its preclinical ‘Allosteric PLK1’ collaboration with Sentinel Oncology into the clinic in 2022 with the program being initially targeted towards Glioma and progress multiple additional internal first-in-class drug discovery programs across both oncology and ageing therapeutic indications.
Led by Dr Chris Torrance CEO, PhoreMost leverages the SITESEEKER® platform to identify new therapeutic targets for any chosen disease setting, and identify how to develop novel drugs to these targets. The company has recently deployed SITESEEKER towards the identification of novel E3-ligands, the progression of which has the potential to be highly disruptive within the important new targeted protein degradation therapeutic modality space.
PhoreMost Raises $46M in Series B Financing | FinSMEs
PhoreMost Ltd., a Cambridge, England, UK-based biopharmaceutical company, raised $46m in Series B funding
Adapttech Raises £2M in Funding
Adapttech, a Birmingham, UK-based biomedical startup, raised £2m in funding.
The round was supported by existing investors including the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia and part of the Midlands Engine Investment Fund, Bionova Capital (formerly Hovione Capital), as well as new investors including ACF Investors, Wealth Club and Wren Capital.
The company intends to use the funds to develop new technologies and grow sales of its system for improving the fitting of prosthetic devices.
The company intends to use the funds for new product developments and sales of its INSIGHT system.
Led by Frederico Carpinteiro, Founder, and Stuart Mead, Chairman, Adapttech provides INSIGHT, which combines a 3D scanner, sensors, wearable technology and a mobile app to make it easier to reach a comfortably fitting prostheses socket and monitor a patient’s rehabilitation process.
Adapttech Raises £2M in Funding | FinSMEs
Adapttech, a Birmingham, UK-based biomedical startup, raised £2m in funding
Komodo Health Raises $220M in Series E Funding
Komodo Health, a NYC- and San Francisco, CA-based health tech company, raised $220m in Series E funding round.
The round was led by Tiger Global Management and joined by Casdin Capital and existing investors ICONIQ Growth, Andreessen Horowitz, and SVB Capital.
The company intends to use the funds to accelerate investment in its enterprise technology platform, application suite, and core data assets.
Founded in 2014 by Arif Nathoo, MD, CEO, and Web Sun, co-founder and president, Komodo Health provides a health platform to deliver patient-level insights by dynamically analyzing the broadest array of data across patients, practitioners, and health systems.
Komodo Health Raises $220M in Series E Funding | FinSMEs
Komodo Health, a NYC- and San Francisco, CA-based health tech company, raised $220m in Series E funding round
Evidation Raises $153M in Series E Funding
Evidation Health, a San Mateo, Calif.-based digital health company, closed a $153m Series E growth funding.
The round was co-led by Omers Growth Equity and Kaiser Permanente Group Trust with participation from existing investors McKesson Ventures and B Capital Group. Teresa Lee, Managing Director, Omers Growth Equity, joined Evidation’s Board of Directors.
The company intends to use the funds to accelerate the expansion of virtual health programs on the platform.
Led by Deborah Kilpatrick, PhD, Co-CEO and Executive Chair, Christine Lemke, Co-founder, Co-Chief Executive Officer, and President, and Luca Foschini, Co-founder & Chief Data Scientist, Achievement is a virtual health company that measures health in everyday life and enables anyone to participate in research and health programs. The company’s platform is used by millions of individuals, generating data with speed and scale.
Evidation Raises $153M in Series E Funding | FinSMEs
Evidation Health, a San Mateo, Calif.-based digital health company, closed a $153m Series E growth funding
Strive Health Raises $140M in Series B Funding
Strive Health, a Denver, CO-based value-based kidney care company, secured a $140m Series B funding round.
The round, which brought total funding to $223.5m, was led by CapitalG, with participation from Redpoint and current investors NEA, Town Hall Ventures, Ascension Ventures and Echo Ventures.
The company intends to use the funds to expand its business reach.
Led by Chris Riopelle, CEO, Strive Health combines advanced technology with patient care to slow kidney disease progression, prevent unnecessary hospitalizations, and expand access to optimal renal replacement therapies such as home dialysis and transplants.
Strive Health Raises $140M in Series B Funding | FinSMEs
Strive Health, a Denver, CO-based value-based kidney care company, secured a $140m Series B funding round
Clarify Health Raises $115M in Series C Funding
Clarify Health, a San Francisco, CA-based enterprise analytics company delivering real-world insights to healthcare organizations, raised $115m in Series C funding.
The round was led by new investor Insight Partners, alongside Spark Capital, Concord Health Partners, and HWVP, with participation from the company’s largest investor, KKR, as well as Rivas Capital and Sigmas Group. In conjunction with the funding, Hilary Gosher, Managing Director at Insight Partners, and Will Reed, General Partner at Spark Capital, will be joining Clarify’s Board of Directors.
The company intends to use the new funds to further scale its self-service healthcare analytics cloud and business applications.
Led by Jean Drouin, MD, CEO, and Todd Gottula, President, Clarify Health is a technology company whose enterprise analytics cloud allows providers, health plans, and life sciences companies to tranform healthcare data into actionable insights to drive growth, optimize networks, improve care delivery, manage population health, maximize value-based care performance, and commercialize pharmaceutical and biotechnology products.
Clarify Health Raises $115M in Series C Funding | FinSMEs
Clarify Health, a San Francisco, CA-based enterprise analytics company delivering real-world insights to healthcare organizations, raised $115m in Series C funding
StrideBio Closes $81.5M Series B Financing
StrideBio, Inc., a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies, closed a $81.5m Series B funding round.
The round was co-led by Northpond Ventures and Novo Holdings A/S and included new investors Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital and UF Innovate Ventures, along with existing investors.
Founded in 2015 based on the research of Mavis Agbandje-McKenna, Ph.D., and Aravind Asokan, Ph.D., and led by Sapan Shah, Ph.D., Chief Executive Officer, StrideBio is a fully integrated gene therapy company focused on creating genetic medicines. Its proprietary structure-inspired adeno-associated viral (AAV) vector engineering platform (STRIVE™) creates differentiated capsids that overcome current limitations of first-generation gene therapies.
StrideBio’s programs will leverage the company’s lead proprietary AAV capsids with features including reduced seroprevalence, neuronal and cardiovascular tropism, liver de-targeting and enhanced gene transfer efficiency compared to first-generation AAV serotypes.
StrideBio Closes $81.5M Series B Financing | FinSMEs
StrideBio, Inc., a Research Triangle Park, N.C.-based developer of novel engineered adeno-associated virus (AAV) based gene therapies, closed a $81.5m Series B funding round
Deerfield-backed Happify Health Targets Mental, Physical Health With $73M Raise
New York-based Happify Health, a software-enabled health care platform to improve mental and physical health, brought in $73 million in capital through Series D and related financing to focus on digital therapeutics and patient care delivery.
The investments, which the company wouldn’t elaborate on, were led by Deerfield Management and included participation from investors including Omega Capital Partners and ION Crossover Fund. In total, Happify has raised $123 million since its inception in 2012, according to Ofer Leidner, co-founder and president of Happify Health.
Leidner and Tomer Ben-Kiki, CEO, started the company to offer an evidence-based platform that delivers scientifically validated programs to positively impact behavior. Users are able to manage chronic conditions via telehealth, access to therapeutics, and Anna, Happify Health’s software-based coach designed to support and engage individuals for several chronic conditions, most notably mental health.
https://news.crunchbase.com/news/deerfield-backed-happify-health-targets-mental-physical-health-with-73m-raise/Aktis Oncology Raises $72M in Series A Financing
Aktis Oncology, a Cambridge, Mass.-based biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers, closed a $72m Series A financing.
The company was founded and incubated by MPM Capital, which co-led the financing with EcoR1 Capital and Vida Ventures, with participation from Octagon Capital, TCG Crossover, Novartis and Bristol Myers Squibb. Aktis Oncology is developing novel alpha radiotherapies to improve upon the efficacy of conventional solid tumor therapies, while limiting toxicity. The company has developed proprietary platforms to discover tumor targeting agents designed with optimal pharmacology for delivering alpha radiotherapy.
Aktis Oncology plans to produce multiple development candidates with potential for efficacy against well-validated cancer targets.
Aktis Oncology Raises $72M in Series A Financing | FinSMEs
Aktis Oncology, a Cambridge, Mass.-based biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers, closed a $72m Series A financing
Ossium Health Raises $63M in Series B Funding
Ossium Health, a San Francisco, CA-based therapeutics company leveraging stem cell science to improve treatment for patients with blood and immune diseases, raised $63m in Series B funding.
The round was co-led by General Catalyst and Vivo Capital with participation from previous investors First Round Capital, Manta Ray Ventures, and XYZ Capital.
Founded in 2016 and run by its Co-Founder, President & CEO Kevin Caldwell, and its Co-Founder, EVP & Chief Science Officer Erik Woods, Ossium Health is a therapeutics company that leverages its deceased donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening blood and immune diseases.
The funds will support an initial suite of clinical trials to use donor-matched hematopoietic stem cells to re-educate the immune systems of organ recipients to accept donor organs, to deploy the anti-inflammatory properties of mesenchymal stem cells to promote healing in patients with fistulizing Crohn’s disease, and to reset the malignant immune systems of hard to match blood cancer patients using bone marrow transplants from organ donors.
Ossium Health Raises $63M in Series B Funding | FinSMEs
Ossium Health, a San Francisco, CA-based therapeutics company leveraging stem cell science to improve treatment for patients with blood and immune diseases, raised $63m in Series B funding
Bigfoot Biomedical Secures Up To $57M in Debt and Equity Financing
Bigfoot Biomedical, a Milpitas, CA-based company dedicated to health outcomes for people with insulin-requiring diabetes, secured new debt and equity financing of up to $57m from Madryn Asset Management.
The company intends to use the proceeds of the investment for commercialization of its Bigfoot Unity™ Diabetes Management Program.
Led by Jeffrey Brewer, CEO, Bigfoot Biomedical partners with health care providers to deliver connected, and comprehensive solutions to support the treatment of Type 1 and Type 2 diabetes.
Currently, the company is anticipating FDA clearance of its Bigfoot Unity System, which features smart pen caps that provide insulin dose decision support and enable patients to follow their doctor’s instructions in simple way.
Bigfoot Biomedical Secures Up To $57M in Debt and Equity Financing
Bigfoot Biomedical, a Milpitas, CA-based company dedicated to health outcomes for people with insulin-requiring diabetes, secured new debt and equity financing of up to $57m from Madryn Asset Management
MedMinder Systems Raises $40M in Funding
MedMinder Systems Inc., a Needham, MA-based fully-integrated, end-to-end pharmacy, medication adherence and connected care solution for elderly and polypharmacy patients, raised $40m in funding.
The round was led by Accelmed Partners with participation from Arkin Holdings and existing investors.
The company intends to use the funds to expand its connected care and telehealth offering, scale its commercial operations by opening additional automated pharmacy locations in high-density metropolitan areas across the U.S., and expand its management, sales and marketing teams with strategic hires.
MedMinder Systems Raises $40M in Funding | FinSMEs
MedMinder Systems Inc., a Needham, MA-based fully-integrated, end-to-end pharmacy, medication adherence and connected care solution for elderly and polypharmacy patients, raised $40m in funding
Gravie Raises $28M in Series D Financing
Gravie, a Minneapolis, MI-based defined contribution healthcare company, raised $28m in Series D financing.
The round was led by AXA Venture Partners, with participation from existing investors FirstMark Capital, Split Rock Ventures and Revelation Partners.
The company intends to use the capital to accelerate continued growth through investments in product and technology, sales and marketing, and expansion into new markets through new and existing distribution channels.
Led by Abir Sen, co-founder and Executive Chairman, Gravie is an innovative health benefits company that allows employers to set to a benefits budget that works for their business, and employees to choose the out-of-pocket maximum that works for them.
Gravie Raises $28M in Series D Financing | FinSMEs
Gravie, a Minneapolis, MI-based defined contribution healthcare company, raised $28m in Series D financing
DexCare Raises $20M in Series A Funding
DexCare, Inc., a Seattle, WA-based digital health company, raised $20M in Series A funding.
The round was led by Define Ventures and including Frist Cressey Ventures, Kaiser Permanente Ventures, SpringRock Ventures and Providence Ventures.
Developed by Providence, one of the largest and most digitally-advanced health systems in the United States, DexCare provides a Platform-as-a-Service (PaaS), an intelligent digital care operating system that manages health system capacity and demand across all lines of care. It has secured half a dozen customers, including Community Health Network, the Froedtert and the Medical College of Wisconsin health network, Houston Methodist, and Providence.
DexCare Raises $20M in Series A Funding | FinSMEs
DexCare, Inc., a Seattle, WA-based digital health company, raised $20M in Series A funding
VLP Therapeutics Raises $16M in Series A Funding
VLP Therapeutics, Inc., a Gaithersburg, Md.-based biotech company, raised US$16m in Series A funding.
Backers included MIYAKO Capital Co., Ltd., Sojitz Corporation, Konishiyasu Co., Ltd., in Japan and Mr. Robert G. Hisaoka, SK Impact Fund, LLC, and RJ Fund in USA.
The company intends to use the funds for research and development of a cancer treatment vaccine, moving into clinical trials at the earliest date possible.
Co-founded in 2013 by Drs. Wataru Akahata, Ryuji Ueno, and Sachiko Kuno, VLP Therapeutics is a biotech company currently engaged in research and development of a cancer treatment vaccine as well as prophylactic vaccines against malaria, dengue, and novel coronavirus disease (COVID-19) using its proprietary platform technologies.
VLP Therapeutics Raises $16M in Series A Funding | FinSMEs
VLP Therapeutics, Inc., a Gaithersburg, Md.-based biotech company, raised US$16m in Series A funding
Riva Health Raises $15.5M in Funding
Riva Health, a Burlingame, California-based mobile cardiology app provider, raised $15.5M in funding.
The round was led by Menlo Ventures with participation from UCHealth and University of Colorado Innovation Fund, as well as Chicago healthcare investors, Brandon Cruz of GoHealth and Larry Gies of Madison Industries. In conjunction with the funding, Dr. Rich Zane from UCHealth will join Greg Yap from Menlo Ventures on Riva’s board of directors.
The company intends to use the funds to expand operations.
Led by CEO Dag Kittlaus, former co-founder of both Siri and Viv, and Tuhin Sinha, PhD and co-founder of one of the largest cardiovascular research studies in the world, Health eHeart, Riva Health is building a cardiology technology app that measures and manages hypertension.
Riva Health Raises $15.5M in Funding | FinSMEs
Riva Health, a Burlingame, California-based mobile cardiology app provider, raised $15.5M in funding
Cylera Raises $10M in Series A Funding
Cylera, a NYC-based healthcare IoT (HIoT) cybersecurity and intelligence company, secured $10m in Series A funding.
The round, which brought total funding to $17m, was led by Concord Health Partners and Maverick Ventures with participation from Concord Health Partners, Maverick Ventures, Contour Venture Partners, Two Sigma Ventures, Dreamit Ventures, Great Oaks Venture Capital, Red Bear Angels and Samsung NEXT.
The company intends to use the funds to expand its presence into new global markets through strategic channel partners, extend the technology into new verticals, to double the headcount across research and development, channel support, customer success, sales and marketing over the next 6 months.
Led by Timur Ozekcin, Co-founder and CEO, Cylera provides a centralized cybersecurity solution that secures the entire connected environment for asset management, risk analysis and threat detection.
Cylera Raises $10M in Series A Funding | FinSMEs
Cylera, a NYC-based healthcare IoT (HIoT) cybersecurity and intelligence company, secured $10m in Series A funding
Instem Acquires d-wise
Instem, a Philadelphia, PA-based provider of IT solutions and services to the global life sciences market, acquired d-wise, Inc., a clinical trial technology and consulting company.
The amount of the deal was not disclosed.
Through the acquisition, Instem will further consolidate key application areas which will help customers streamline and accelerate their research and development processes, while access to a broader range of data from across the R&D continuum will increase the power of future in silico modelling and prediction solutions.
Instem Acquires d-wise | FinSMEs
Instem, a Philadelphia, PA-based provider of IT solutions and services to the global life sciences market, acquired d-wise, Inc., a clinical trial technology and consulting company
Fulcrum Equity Partners Closes Growth Fund IV, at $275M
Fulcrum Equity Partners, an Atlanta, GA-based growth equity firm investing in healthcare services, HCIT, B2B SaaS, and tech-enabled services, closed its fourth fund, with $275m in committed capital.
Fulcrum Growth Fund IV was oversubscribed and supported by existing and new institutional investors and family offices.
Led by Founding Partners Tom Greer and Jeff Muir, Fulcrum invests $4 to $25 million and works alongside management to build backed companies within healthcare services, HCIT, B2B SaaS, and technology-enabled services into scalable, professionally-run organizations, assisting in attracting talent, executing strategic initiatives, and implementing operational discipline.
